NO20040330L - Fremgangsmate, sammensetninger og sett vedrorende chitinaser og chitinase-lignende molekyler og inflammatorisk sykdom - Google Patents

Fremgangsmate, sammensetninger og sett vedrorende chitinaser og chitinase-lignende molekyler og inflammatorisk sykdom

Info

Publication number
NO20040330L
NO20040330L NO20040330A NO20040330A NO20040330L NO 20040330 L NO20040330 L NO 20040330L NO 20040330 A NO20040330 A NO 20040330A NO 20040330 A NO20040330 A NO 20040330A NO 20040330 L NO20040330 L NO 20040330L
Authority
NO
Norway
Prior art keywords
chitinases
chitinase
molecules
compositions
sets
Prior art date
Application number
NO20040330A
Other languages
English (en)
Norwegian (no)
Inventor
Jack A Elias
Zhou Zhu
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of NO20040330L publication Critical patent/NO20040330L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2442—Chitinase (3.2.1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01014—Chitinase (3.2.1.14)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20040330A 2001-07-24 2004-01-23 Fremgangsmate, sammensetninger og sett vedrorende chitinaser og chitinase-lignende molekyler og inflammatorisk sykdom NO20040330L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30743201P 2001-07-24 2001-07-24
PCT/US2002/023516 WO2003009808A2 (en) 2001-07-24 2002-07-23 Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease

Publications (1)

Publication Number Publication Date
NO20040330L true NO20040330L (no) 2004-03-09

Family

ID=23189747

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040330A NO20040330L (no) 2001-07-24 2004-01-23 Fremgangsmate, sammensetninger og sett vedrorende chitinaser og chitinase-lignende molekyler og inflammatorisk sykdom

Country Status (13)

Country Link
US (6) US7214373B2 (de)
EP (1) EP1418813A4 (de)
JP (1) JP2006508014A (de)
KR (1) KR20040053100A (de)
AU (1) AU2002319680B2 (de)
BR (1) BR0211468A (de)
CA (1) CA2454342A1 (de)
HU (1) HUP0400659A3 (de)
IL (2) IL160000A0 (de)
MX (1) MXPA04000769A (de)
NO (1) NO20040330L (de)
PL (1) PL369010A1 (de)
WO (1) WO2003009808A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2457565A1 (en) * 2001-10-09 2003-04-17 Genentech, Inc. Novel acidic mammalian proteins and polynucleotides encoding the same
US20040170621A1 (en) * 2002-08-30 2004-09-02 Roodman G. David Method of resisting osteoclast formation
US7364846B2 (en) * 2002-10-11 2008-04-29 Molecular Devices Corporation Gene expression profiling from FFPE samples
WO2004092404A2 (en) * 2003-04-11 2004-10-28 Wyeth Inhibitors of acidic mammalian chitinase as asthma therapeutics
EP1729805A4 (de) * 2004-02-25 2008-11-26 Medimmune Inc Verfahren und zusammensetzungen im zusammenhang mit chitinasen und chitinase-artigen molekülen und modulierung von osteoklasten
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
EP1928496A4 (de) * 2005-08-31 2011-01-05 Medimmune Inc C/clp-antagonisten und anwendungsverfahren
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
WO2008144646A1 (en) * 2007-05-18 2008-11-27 Wyeth Novel primate chitinases and uses therefor
CA2739944A1 (en) * 2008-01-23 2009-07-30 Rigshospitalet Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40
CA2740028A1 (en) 2008-01-23 2009-07-30 Herlev Hospital Ykl-40 as a general marker for non-specific disease
AU2009276223B2 (en) * 2008-08-01 2015-04-02 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US11150250B2 (en) * 2008-08-28 2021-10-19 Astute Medical, Inc. Methods for diagnosing acute kidney injury or renal failure
EP2813848A3 (de) * 2008-08-29 2015-03-11 Astute Medical, Inc. Verfahren und Zusammensetzungen zur Diagnose und Prognose von Nierenläsion und Niereninsuffizienz
US8580520B2 (en) 2008-09-15 2013-11-12 Herlev Hospital YKL-40 as a marker for gastrointestinal cancers
CN103760359B (zh) 2008-10-21 2017-01-11 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
NZ619918A (en) * 2008-10-21 2015-04-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BRPI0922021A2 (pt) 2008-11-10 2019-09-24 Astute Medical Inc método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal
US20110229915A1 (en) * 2008-11-22 2011-09-22 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US7851616B2 (en) * 2008-12-04 2010-12-14 Mingchi University Of Technology Development of asthma therapy with rAAV-mediated AMCase shRNA
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011017654A1 (en) 2009-08-07 2011-02-10 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102725635B (zh) 2009-11-07 2015-05-20 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
ES2818138T3 (es) 2009-12-20 2021-04-09 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
KR101940014B1 (ko) 2010-02-05 2019-01-21 아스튜트 메디컬 인코포레이티드 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
AU2011220413B2 (en) 2010-02-26 2015-07-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ703055A (en) 2010-06-23 2016-07-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011269775B2 (en) 2010-06-23 2015-01-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
PT2655388T (pt) 2010-12-23 2016-09-06 Merck Sharp & Dohme Inibidores de glicosidase seletivos e as suas utilizações
EP2691407B1 (de) 2011-03-31 2017-02-22 Alectos Therapeutics Inc. Selektive glycosidasehemmer und ihre verwendung
EP2726492B1 (de) 2011-06-27 2017-11-01 Alectos Therapeutics Inc. Selektive glycosidasehemmer und ihre verwendung
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
WO2013130594A1 (en) * 2012-02-27 2013-09-06 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2890676B1 (de) 2012-08-31 2018-12-05 Alectos Therapeutics Inc. Glycosidasehemmer und verwendungen davon
US9809537B2 (en) 2012-08-31 2017-11-07 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
KR20150079711A (ko) 2012-10-31 2015-07-08 알렉토스 테라퓨틱스 인크. 글리코시다아제 저해제 및 이의 용도
ES2926197T3 (es) 2013-01-17 2022-10-24 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
GB2521675B (en) 2013-12-31 2015-11-11 Houman Taheri Amlashi Generating electricity
JP6209289B2 (ja) * 2014-10-22 2017-10-04 サントリーホールディングス株式会社 環状ジペプチドを有効成分とする皮膚保湿機能改善剤
EP3233106B1 (de) 2014-12-18 2023-02-01 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz
WO2016136991A1 (ja) * 2015-02-27 2016-09-01 味の素株式会社 唾液中マーカータンパク質を用いた低栄養状態の判定方法、及びそれに使用する診断薬
CA3026502A1 (en) 2016-06-06 2017-12-14 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
WO2019036566A1 (en) 2017-08-17 2019-02-21 Brown University METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF FIBROSIS
JP7267562B2 (ja) * 2018-05-21 2023-05-02 学校法人東京薬科大学 免疫調節作用を有する単球およびその使用方法
CN108926708A (zh) * 2018-07-31 2018-12-04 张家港市第人民医院 过敏性鼻炎小鼠模型复制方法及应用
BR112022018741A2 (pt) * 2020-04-03 2022-11-01 Standard Of Care Corp Composições de hialuronidase e/ou 4-metilumbeliferona aerossolizadas e métodos de uso das mesmas para tratar doenças ou distúrbios respiratórios
WO2024073612A2 (en) * 2022-09-30 2024-04-04 Cedars-Sinai Medical Center Therapeutic nucleic acids and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5070191A (en) * 1989-04-27 1991-12-03 Ajinomoto Co., Inc. Demethylallosamidin and a process for production thereof
JP3063930B2 (ja) * 1991-01-31 2000-07-12 味の素株式会社 アロサミジン化合物及びその製造法
WO1994028889A1 (en) * 1993-06-08 1994-12-22 Neogenix, Inc. Purified natural and synthetic compounds for the treatment of osteoarthritis
US7229770B1 (en) * 1998-10-01 2007-06-12 The Regents Of The University Of California YKL-40 as a marker and prognostic indicator for cancers
CA2164498C (en) * 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
IL115744A (en) * 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
JP3634891B2 (ja) 1995-04-06 2005-03-30 株式会社海洋バイオテクノロジー研究所 キチナーゼ阻害物質
US5773259A (en) * 1996-03-20 1998-06-30 Smithkline Beecham Corporation Tissue remodeling proteins
US5843449A (en) 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
EP0828752A4 (de) 1996-03-29 2000-07-26 Smithkline Beecham Corp Chitotriosidase
EP0805206A3 (de) * 1996-05-03 1999-09-15 Smithkline Beecham Corporation Menschliches Glycoprotein aus Knorpel
US5811535A (en) * 1996-08-09 1998-09-22 Smithkline Beecham Corporation Human cartilege gp39-like gene
IL122233A (en) * 1996-12-06 2001-04-30 Akzo Nobel Nv Method of generating monoclonal antibodies to cell wall and pharmaceutical preparations and diagnostic agents containing them
US6200951B1 (en) 1998-03-12 2001-03-13 Icos Corporation Chitinase chitin-binding fragments
US6060590A (en) * 1998-03-31 2000-05-09 The Regents Of The University Of California Chitinase related proteins and methods of use
EP1100526A2 (de) 1998-07-23 2001-05-23 Akzo Nobel N.V. Verwendung von hc gp-39 in immunerkrankungen
RU2233290C2 (ru) 1998-07-23 2004-07-27 Акцо Нобель Н.В. Новые пептиды для применения в иммунотерапии аутоиммунных заболеваний
JP2000327575A (ja) 1999-05-26 2000-11-28 Teika Seiyaku Kk ジケトピペラジン誘導体含有炎症疾患治療剤および新規なジケトピペラジン誘導体
ATE328080T1 (de) * 1999-11-15 2006-06-15 Takeda Pharmaceutical Proteine und für diese kodierende dna
AU2001283327A1 (en) * 2000-08-14 2002-02-25 Human Genome Sciences, Inc. 8 human secreted proteins
EP1319184B1 (de) 2000-08-14 2007-07-25 N.V. Organon Verwendung von antikörpern gegen spezifische mhc-peptidkomplexe
DE10046267A1 (de) 2000-09-19 2002-03-28 Bayer Ag Verwendung von Riboflavin und Flavinderivaten als Inhibitoren von Chitinasen
US20030087414A1 (en) * 2001-11-02 2003-05-08 Aerts Johannes Maria Franciscus Gerardus Mammalian mucinase, its recombinant production, and its use in therapy or prophylaxis against diseases in which mucus is involved or infectious diseases
US20040170621A1 (en) * 2002-08-30 2004-09-02 Roodman G. David Method of resisting osteoclast formation
US8053563B2 (en) 2005-02-28 2011-11-08 Bio-Y A/S YKL-40 monoclonal authority

Also Published As

Publication number Publication date
EP1418813A4 (de) 2009-03-04
US7214373B2 (en) 2007-05-08
IL160000A0 (en) 2004-06-20
KR20040053100A (ko) 2004-06-23
EP1418813A2 (de) 2004-05-19
US20090162347A1 (en) 2009-06-25
MXPA04000769A (es) 2005-09-21
AU2002319680B2 (en) 2008-04-10
US8679503B2 (en) 2014-03-25
IL160000A (en) 2010-06-16
US20030049261A1 (en) 2003-03-13
WO2003009808A3 (en) 2003-09-04
CA2454342A1 (en) 2003-02-06
US20090149410A1 (en) 2009-06-11
US20090148539A1 (en) 2009-06-11
PL369010A1 (en) 2005-04-18
HUP0400659A2 (hu) 2005-02-28
JP2006508014A (ja) 2006-03-09
US20130136751A1 (en) 2013-05-30
HUP0400659A3 (en) 2005-06-28
BR0211468A (pt) 2004-11-23
US20060063728A1 (en) 2006-03-23
WO2003009808A2 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
NO20040330L (no) Fremgangsmate, sammensetninger og sett vedrorende chitinaser og chitinase-lignende molekyler og inflammatorisk sykdom
DK1858488T4 (da) Tigecyclinsammensætninger og fremgangsmåder til fremstilling deraf
FI20021772A (fi) Uudet hiilihydraattikoostumukset ja menetelmä niiden valmistamiseksi
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
NO20055837D0 (no) Immunsupprimerende forbindelser og sammensetninger
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
DK2377931T3 (da) Varianter af glycosidhydrolase
DE60234487D1 (de) Adaptive Differentialmikrofonanordnung zweiter Ordnung
IS7261A (is) N-adamantýlmetýlafleiður og milliefni sem lyfjablöndur og aðferðir til að framleiða þær
NO20033565L (no) Acylerte indanylaminer og deres anvendelse som farmasöytiske midler
DE60236532D1 (de) Abtastinterferometer für asphärische oberflächen und wellenfronten
DK2302055T3 (da) Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
DK1392282T3 (da) Dermatologiske og kosmetiske sammensætninger, der omfatter et furfurylderivat
DE602004018896D1 (de) Duplexer und Herstellungsverfahen
DE60223735D1 (de) Interferometer und zugehöriges Herstellungsverfahren
DK1667730T3 (da) Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom
JP2006502186A5 (ja) β-グルカンの使用
DK1896077T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af inflammatoriske sygdomme
DE602005020712D1 (de) Anschlussklemme und Herstellungsverfahren
NO20023678L (no) Behandling av allergiske og inflammatoriske tilstander
NO20021569L (no) Rensete kitiner og fremgangsmåte for deres fremstilling
DK1455750T3 (da) Viscoelelastiske oftalmologiske sammensætninger, der omfatter hyaluronsyre og chondroitinsulfat
ATE368722T1 (de) Waschmittelbehandlungzusammensetzungen
FI20011630A0 (fi) Karsintalaitteisto
NO20033743L (no) Fremgangsmåte og fremstilling citalopram

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application